Showing results (191-200 of 207) with videos related to

Sort By:
Pageof 21
Molecular and Cellular Biology|December 28, 1999
Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathwayR J Lee, C Albanese, M Fu, et al.
Mediators of Inflammation|December 2, 2014
Inhibition of ocular aldose reductase by a new benzofuroxane derivative ameliorates rat endotoxic uveitisC Di Filippo, M V Zippo, R Maisto, et al.
Mediators of Inflammation|March 8, 2016
Activation of Melanocortin Receptors MC 1 and MC 5 Attenuates Retinal Damage in Experimental Diabetic RetinopathyS Rossi, R Maisto, C Gesualdo, et al.
Mediators of Inflammation|April 19, 2021
Corrigendum to "Activation of Melanocortin Receptors MC<sub>1</sub> and MC<sub>5</sub> Attenuates Retinal Damage in Experimental Diabetic Retinopathy"S Rossi, R Maisto, C Gesualdo, et al.
Access Microbiology|February 17, 2025
Genome sequences of pathogenic and non-pathogenic Pantoea ananatis strains in maize (Zea mays L.)Izabela Moura Duin, Viviane Yumi Baba, Katherine M D'Amico-Willman, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita|February 10, 2021
Public health and clinical approach to proactive management of frailty in multidimensional arenaR Roller-Wirnsberger, G Liotta, S Lindner, et al.
The Review of Scientific Instruments|April 5, 2017
Chemical aerosol Raman detectorR L Aggarwal, L W Farrar, S Di Cecca, et al.
NPJ Breast Cancer|June 9, 2025
Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer preventionG Aurilio, D Serrano, M Lazzeroni, et al.
Minerva Anestesiologica|September 21, 2023
Feasibility, safety and efficacy of COVID-19 severe acute respiratory distress syndrome management without invasive mechanical ventilationFrancesca Guzzo, Gaetano Lombardi, Margherita Tozzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestC Cremolini, F Loupakis, C Antoniotti, et al.
Pageof 21